Cue Biopharma, Inc.
CUE Biopharma, Inc. (NASDAQ: CUE) is a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics designed to selectively engage and modulate disease-specific T cells for treating autoimmune and inflammatory diseases. The company's website is www.cuebiopharma.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cue Biopharma, Inc. does
In the company’s own words
CUE Biopharma, Inc. (NASDAQ: CUE) is a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics designed to selectively engage and modulate disease-specific T cells for treating autoimmune and inflammatory diseases. The company's website is www.cuebiopharma.com.
The company's core technology platform, called Immuno-STAT, represents a differentiated approach to immunotherapy that selectively modulates disease-relevant T cells while enhancing efficacy and minimizing off-target effects, unlike conventional approaches that broadly activate the immune system. This modular platform enables the company to deploy similar functional elements across diverse therapeutic approaches to restore immune balance.
CUE Biopharma's pipeline includes three primary series of drug candidates. The CUE-400 series targets autoimmune diseases by exploiting transforming growth factor beta and interleukin-2 signaling to induce anti-inflammatory processes and foster regulatory T cell proliferation, with CUE-401 as the lead candidate for which the company is preparing to file an investigational new drug application in the second quarter of 2026. The CUE-500 series redirects anti-viral killer T cells to target and eliminate pathogenic cells, including CUE-501 for autoimmune B cell depletion, which has been licensed to Boehringer Ingelheim International GmbH. The CUE-100 series, originally developed for oncology applications including CUE-101 for HPV-positive cancers and CUE-102 for WT1-expressing cancers, has been licensed to ImmunoScape Pte. Ltd. for development as part of a novel seed-and-boost immunotherapy combining the company's T-cell engagers with proprietary tumor-specific T cell receptors.
The company holds an exclusive worldwide license to core technology patents from Albert Einstein College of Medicine relating to engineering biologics to control T cell activity. As of December 31, 2025, CUE Biopharma owned or had licensed 161 issued patents, including 31 U.S. patents, along with 308 pending patent applications. The company has established strategic collaborations to advance its pipeline while focusing internal resources on CUE-401 development for autoimmune indications, positioning itself to potentially establish new standards of care in treating T cell-mediated diseases.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1645460
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cue Biopharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cue Biopharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cue Biopharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cue Biopharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cue Biopharma, Inc.'s last four quarterly filings that the numbers alone won't show?”